Aug 2026
Network pharmacology and experimental verification reveal the mechanism of hederagenin in suppressing podocyte injury in focal segmental glomerular sclerosis.
In vivo and in vitro experiments demonstrated that HDG alleviated renal injury in ADR-induced FSGS in mice and attenuated TGF-β1-induced damage in MPC5 cells, which support HDG as a promising therapeutic candidate for FSGS treatment.
Xinyuan Tian, Rang-yue Han, Xiao-Jiao Gu et al.
· Clinical Nephrology · 0 citations